ArticleDiscover oncology2026
Bioinformatics analysis identifies AURKB as a prognostic biomarker across multiple human cancers.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is a major global health issue. Aurora kinase B (AURKB) is known to regulate cell division and linked to poor prognosis in some cancers, but its role across all cancer types is unclear.
objectiveThe goal of this study is to examine how AURKB expression, epigenetic regulation, and immune cell infiltration relate to its potential as a prognostic biomarker.
methodsWe conducted a comprehensive analysis of transcriptomic and clinical data from TCGA, HPA, and CCLE to assess AURKB expression in various cancers. RNA-seq data processing involved TCGAbiolinks, normalization to TPM, and filtering based on the completeness of survival data and sequencing quality. The maxstat method was used to categorize groups into high and low expression. The prognostic significance was evaluated using Cox regression and Kaplan-Meier analysis for OS, DFS, PFI, and DSS. UALCAN was used to analyze promoter methylation, and immune infiltration was assessed with TIMER2 and CIBERSORT. Using the GDSC and CTRP datasets, researchers carried out functional enrichment (KEGG, GO) and examined drug sensitivity correlations. With more than 11,000 cases, the sample size provided enough statistical power.
resultsAURKB was found to be significantly overexpressed in multiple malignancies, including breast (BRCA), liver (LIHC), kidney (KIRP), and lung (LUAD) cancers, with high expression linked to advanced clinical stages and poorer prognosis. Elevated AURKB levels were associated with significantly reduced OS, DFS, PFI and DSS, particularly in cancers like KIRP (HR = 2.04 for OS, p < 4.2e-10). ROC analysis demonstrated the high diagnostic potential of AURKB, with Area Under the Curve (AUC) values of 1.000 for CHOL and GBM, indicating strong sensitivity and specificity. Additionally, AURKB overexpression was often accompanied by promoter hypomethylation, suggesting an epigenetic mechanism underlying its dysregulation. Immune infiltration analysis revealed that increased AURKB expression correlated with reduced CD8 + T cell infiltration and enhanced immune suppression, particularly in aggressive subtypes. Drug sensitivity analysis showed a negative correlation between AURKB expression and chemotherapy response, suggesting that AURKB overexpression contributes to drug resistance.
conclusionAURKB is a significant prognostic biomarker and potential therapeutic target, with overexpression linked to poor outcomes and chemotherapy resistance. The association with hypomethylation suggests an epigenetic role, supporting targeted therapies. AURKB's influence on immune suppression highlights its role in the tumor microenvironment. Clinical integration of AURKB analysis could enhance personalized treatment, and future research should explore combination therapies with AURKB inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.